Jin Yang-gon, Chairman of HLB Group, has purchased additional shares of HLB Pangaea.
On February 25, HLB Pangaea announced that Chairman Jin, after buying 205,064 shares on the market earlier this month, additionally acquired a total of 94,747 shares between February 13 and February 23.
HLB Pangaea is pursuing a mid- to long-term strategy to develop its antibody-oligonucleotide conjugate (AOC) structure not only for single new drug development, but also into a repeatedly applicable platform. The company plans to secure platform competitiveness that can be expanded beyond specific indications to a wide range of diseases, including central nervous system (CNS) disorders, muscular diseases, and rare genetic diseases.
An HLB Pangaea official said, "AOC is a next-generation platform that combines antibody-based precision delivery technology with nucleic acid therapeutics, and it has a structure that can expand into various disease areas beyond conventional antibody-drug conjugates (ADC), which have been centered on anticancer therapies," adding, "By leveraging our proprietary peptide nucleic acid (PNA)-based core technology, we aim to secure platform competitiveness that allows repeated use, and we plan to gradually expand the scope of application, starting with rare diseases."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
